On May 28, 2019 Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, reported that it will present data from the Phase 1/2 study of its proprietary, selective cortisol modulator, relacorilant, in combination with nab-paclitaxel (Abraxane) in patients with solid tumors, at the 2019 annual meeting of the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) in Chicago, Illinois (May 31 – June 4) (Press release, Corcept Therapeutics, MAY 28, 2019, https://ir.corcept.com/news-releases/news-release-details/corcept-therapeutics-present-data-phase-12-trial-relacorilant [SID1234536593]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Our Phase 1/2 trial of relacorilant in combination with nab-paclitaxel has been productive," said Andreas Grauer, MD, Corcept’s Chief Medical Officer. "Encouraging results in patients with platinum-resistant ovarian cancer prompted us, after consultation with our investigators, to initiate a 180-patient, controlled Phase 2 trial of relacorilant plus nab-paclitaxel in that indication earlier this year. We look forward to sharing additional data in patients with a variety of solid tumors."
Monday, June 3rd
Relacorilant (RELA) with nab-paclitaxel (NP): Safety and
activity in patients with pancreatic ductal adenocarcinoma
(PDAC) and ovarian cancer (OvCA)
P. Munster; S. Shepard Gastrointestinal (Noncolorectal) Cancer
Poster Board: #235
Time: 8:00 – 11:00 am
Location: Hall A
Selective and nonselective GR antagonists in combination
with chemotherapy in ovarian cancer PDX models
J. Veneris; G. Fleming Gynecologic Cancer
Abstract No: e17039
About Relacorilant
Relacorilant is a non-steroidal, selective modulator of the glucocorticoid receptor, one of the two receptors to which cortisol binds. Relacorilant does not bind to the body’s other hormone receptors, including the progesterone receptor. Corcept is studying relacorilant as a potential treatment for a variety of serious disorders. Current trials include a 180-patient, controlled Phase 2 trial of relacorilant combined with nab-paclitaxel in patients with platinum-resistant ovarian cancer and a Phase 3 trial of relacorilant as monotherapy for patients with Cushing’s syndrome. Relacorilant is proprietary to Corcept and is protected by composition of matter and method of use patents through 2037. Relacorilant has received orphan designation in the United States for the treatment of both Cushing’s syndrome and pancreatic cancer.